Mr. Green has more than 30 years of experience in the global pharmaceutical and healthcare services industry, with significant expertise in the contract manufacturing of novel pharmaceutical products. His global pharmaceutical experience spans across 4 continents, having run 31 facilities in nine countries covering North America, South America, Europe, and Asia. Green most recently served as president and CEO of Therapure Biopharma, where he oversaw the growth of the company’s CDMO business, while also leading the creation of Therapure’s proprietary plasma protein business, named Evolve. Prior to Therapure, he held a number of senior management roles, most notably acting as managing director for Nipa Laboratories Ltd. Other attained roles include acting as the head of the life science division of Clariant International Ltd (in the USA), becoming president and CEO of Rhodia Pharma Solutions Ltd. and also becoming president of Codexis (Inc.’s pharma division).
Having relaunched itself in 2018, Avid Bioservices says it is going from strength-to-strength in the contract manufacturing space and its strategy will continue with a new CEO.
Avid Bioservices emerged from drug developer 'Peregrine Pharmaceuticals' in January of 2018 as a contract development and manufacturing organization (CDMO). Previously, Avid were a product development organization, with manufacturing facilities to support the scale of their pipeline.
While they were focused on developing products, they were also offering services for process development and manufacturing. With their excess capacity, the decision was made to divest the entire portfolio of their pipeline and focus being Avid Bioservices, a dedicated CDMO. Avid is in “growth mode” and continuous assessment will be given to plans for an expansion at a 42,000 square-foot shell next to one of its facilities in Tustin.
Avid’s business model is unlikely to change with the introduction of a new CEO. Avid have established themselves in the CDMO industry and, as such, have a respectable portfolio of specialised skills, as well as promising molecules at varying stages that they are currently working on. The company does not seek deviation and so plan to continue down the same pathway.